Literature DB >> 6156229

Block of axoplasmic transport in vitro by vinca alkaloids.

S Y Chan, R Worth, S Ochs.   

Abstract

The three potent antimitotic vinca alkaloids: vincristine (VCR), vinblastine (VLB), and vindesine (VDS) were compared for their effect in blocking axoplasmic transport in vitro using a desheathed preparation of the peroneal branch of cat sciatic nerve. A range of vinca alkaloid concentrations from 1-100 microM was examined. The relative order of potency in blocking axoplasmic transport was VCR greater than VLB greater than VDS at a concentration of 25 microM. At the higher concentrations block occurred so rapidly that a statistically significant difference between these agents could not be obtained. The relation of vinca block to the transport mechanism is discussed.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6156229     DOI: 10.1002/neu.480110304

Source DB:  PubMed          Journal:  J Neurobiol        ISSN: 0022-3034


  5 in total

Review 1.  A paradigm for examining toxicant effects on viability, structure, and axonal transport of neurons in culture.

Authors:  D J Brat; S Brimijoin
Journal:  Mol Neurobiol       Date:  1992 Summer-Fall       Impact factor: 5.590

2.  Axotomy-induced ornithine decarboxylase activity in the mouse dorsal root ganglion is inhibited by the vinca alkaloids.

Authors:  A I Soiefer; A Moretto; P S Spencer; M I Sabri
Journal:  Neurochem Res       Date:  1988-12       Impact factor: 3.996

Review 3.  Chemotherapy-induced peripheral neuropathy: A current review.

Authors:  Nathan P Staff; Anna Grisold; Wolfgang Grisold; Anthony J Windebank
Journal:  Ann Neurol       Date:  2017-06-05       Impact factor: 10.422

Review 4.  Prevention and management of drug-induced peripheral neuropathy.

Authors:  L L Olesen; T S Jensen
Journal:  Drug Saf       Date:  1991 Jul-Aug       Impact factor: 5.606

5.  Aspects of vincristine-induced neuropathy in hematologic malignancies: a systematic review.

Authors:  Marie Lindhard Madsen; Hanne Due; Niels Ejskjær; Paw Jensen; Jakob Madsen; Karen Dybkær
Journal:  Cancer Chemother Pharmacol       Date:  2019-06-18       Impact factor: 3.333

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.